Search General Info
Search Education
Search Partnering Companies
Navigo Proteins
2:45 PM - 3:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Navigo Proteins is a fast-growing German biotech developing next-generation targeted therapeutics, based on novel, proprietary target binding proteins called Affilin®. Our Precision Targeting Toolbox offers customized mono, bi-/ or multi-specific Affilin® which can be coupled to various functional moieties like cytotoxic payloads and radioactive isotopes. Together with our proprietary half-life optimizing modules called HEAD®, we create Afflin®-based therapies, with superior targeting and an optimized in vivo distribution.
With a focus in precision oncology and a drive to bring innovative, best-in-class therapies to patients, the Navigo team is designing novel Affilin® against Tumor Associated Antigens (TAAs) as well as immuno-oncology (I/O) targets. With a growing portfolio of ‘Off-the shelf’ Affilin® directly available for partnering, and promising pre-clinical data, Navigo is looking for strategic partnerships to (co-) develop and commercialize Affilin®-based biopharmaceuticals.
With a focus in precision oncology and a drive to bring innovative, best-in-class therapies to patients, the Navigo team is designing novel Affilin® against Tumor Associated Antigens (TAAs) as well as immuno-oncology (I/O) targets. With a growing portfolio of ‘Off-the shelf’ Affilin® directly available for partnering, and promising pre-clinical data, Navigo is looking for strategic partnerships to (co-) develop and commercialize Affilin®-based biopharmaceuticals.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1521741-1-JPG.png)
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Saxony-Anhalt
Company HQ Country:
Germany
Year Founded:
2017
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
HER2-Affilin® Radioligand therapy
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-SahasrabudheP.png)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved